Seeking Alpha: Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward

The biotech sector has gotten a little "interesting" since drug pricing re-emerged as a tempting target for political soundbites and investors started looking back on just how far the sector has come in terms of valuation and multiples. Alnylam Pharmaceuticals (NASDAQ:ALNY) has taken its share of drubbing, with the shares down about 20% since my last piece on concerns about the implications of potential drug pricing reforms on its largely orphan drug-focused pipeline, as well as concerns relating to the company's Phase III revusiran program.

I wasn't thrilled with the valuation back in June, but I think the combination of the share price performance and the company's clinical updates makes for a more interesting opportunity today. Time will tell whether my estimates and model are reasonable, conservative, or aggressive, but I do see significant value-add potential over the next six months as more information comes out on programs like ALN-CC5, ALN-AT3, ALN-GO1, and the core TTR platform.

Click here for the full article:
Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward